Recruiting
Phase 1

THU & DEC

Sponsor:

Treebough Therapies

Code:

NCT07006025

Conditions

MDS

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Decitabine

Study Details

Brief summary:

The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome. The main questions it aims to answer are:

  • Does the combination drug exhibit hematological and nonhematological toxicity?
  • Does the combination drug improve health status and reduce the number of days of hospitalization?

Participants will:

  • Take tetrahydrouridine and decitabine once a week for 24 weeks
  • Visit the clinic once every 4 weeks for checkups and tests
  • Keep a diary of their symptoms

Conditions

MDS

Study ID

NCT07006025

Start date

Jun 3, 2025

Status verified date

Jan, 2026

Completion date

Mar 30, 2027

Anticipated

Primary completion date

Dec 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must have a diagnosis of MDS that has received one or more prior standard therapies and is relapsed or refractory
  • Patients must be 18 years of age or older
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3
  • Patients must have adequate end-organ function
  • Patient's body weight must be ≥ 41 kg
  • Subjects must be able to understand and willing to sign a written informed consent document and complete study-related procedures.

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia (APL)
  • Prior treatment with ≥4 28-day cycles of parenteral or oral decitabine
  • No other disease-directed therapy, save for hydroxyurea, including experimental or investigational drug therapy for 14 days prior to study entry (hydroxyurea should be discontinued ≥24 hours prior to initiation of study drug)
  • Requiring concomitant treatment with drugs that are cytidine deaminase (CDA) substrates and/or inhibitors, e.g., cytarabine, 5-azacytidine, gemcitabine
  • Currently pregnant or breastfeeding. Females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment start.
  • Uncontrolled intercurrent illness that could limit life expectancy or ability to complete study correlates
  • Women of Childbearing Potential (WOCBP) who are unwilling to agree to use dual contraceptive measures (i.e., hormonal or barrier method of birth control; abstinence, condom) prior to study entry, for the duration of study participation, and until 6 months after taking the last dose of THU/decitabine
  • Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a WOCBP, beginning at the screening visit and continuing until 6 months after taking the last dose of THU/decitabine
  • 9\. Patients with uncontrolled active human retrovirus (HIV) infection, as this will further increase the risk for opportunistic infections. However, patients with HIV with undetectable viral load by polymerase chain reaction (PCR), without opportunistic infection, and on a stable regimen of antiretroviral therapy are eligible

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Active

Oral capsules of THU followed 1 hour later by decitabine

Interventions

Decitabine

Oral tetrahydrouridine and oral decitabine capsule

Primary outcome measure

  • White blood cell measurement [ Time Frame: every 4 weeks ]
  • Platelet count [ Time Frame: every 4 week ]

Central Contacts and Locations

Central contacts

Davina Hoban

201-618-4725dhoban@montefiore.org

Locations

Montefiore Einstein Medical Center

Recruiting

The Bronx, New York, United States, 10467

Contacts

Davina Hoban

201-618-4725dhoban@montefiore.org

Principal Investigator:

Mendel Goldfinger, MD

More Information

Sponsor

Treebough Therapies

Last update posted

Jan 15, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Treebough Therapies on 2026-01-15.